Exclusive Summary

• Tobramycin Sulfate for Injection is a WHO essential medicine and guideline-recommended drug, possessing clear global clinical demand and market foundation.
• Original patents have expired, presenting significant generic opportunities in a highly competitive yet large market.
• Chinese manufacturing's cost advantage combined with potential international certifications makes it highly price competitive in the global generic market.
• Its injectable formulation holds irreplaceable clinical value in specific infections and severe treatment, securing its market position.
• In certain emerging markets, generic versions have substantial substitution potential due to the high cost of originator drugs.